Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) has announced a major advancement in its proprietary Mueller iodine extraction process, reporting successful laboratory production of iodine at 99.8% purity with an overall recovery rate exceeding 90%. The company, a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is now preparing for field pilot testing of a mobile unit capable of processing up to 80,000 liters of oilfield brine per day.
This development is significant because it moves the Mueller process beyond bench-scale validation toward continuous, real-world field operation. The process is designed to recover high-purity iodine from iodine-rich oilfield brine, which is typically treated as waste by oil and gas producers. By extracting iodine, Voyageur aims to establish a domestic supply chain for this critical raw material used in iodinated contrast media, reducing reliance on imports and potentially lowering costs for medical imaging agents.
The Houston, Texas-based laboratory and fabrication site has been using produced water from the Anadarko and Permian Basins to demonstrate the process under controlled conditions. Key achievements include continuous operation using real oilfield brine feed, generation of clean brine suitable for disposal or reinjection, and validation of process parameters supporting scale-up. The company has also completed a preliminary design basis for a 200 metric tonne per year plant and conducted techno-economic and environmental validation, indicating a low-cost operational expenditure and environmental profile.
The field pilot unit, which is transportable and sized for 80,000 liters per day, is scheduled to commence field testing in the coming weeks, with operations planned for September 2026. Field testing will provide operating data under real-world conditions, informing the design of modular, relocatable production units that could be deployed at multiple saltwater disposal sites. The modular concept involves producing iodine concentrate at various sites and transporting it to a central hub for final polishing, prilling, and packaging.
Brent Willis, President and CEO of Voyageur, emphasized the importance of this milestone: "Achieving 99.8% purity and greater than 90% recovery in laboratory testing using real oilfield brine provides meaningful technical validation as we prepare for field pilot operations. This work supports our broader strategy of building a secure, vertically integrated supply chain for radiology drugs."
The strategic implications are far-reaching. For oil and gas operators and produced water midstream companies, this technology offers a new revenue stream from a waste product. Billions of barrels of produced brine are handled and disposed of each year at significant cost, yet only a small fraction of the iodine they contain is recovered. Voyageur's goal is to be the first to economically profit from this resource, potentially transforming brine from a liability into an asset.
For the medical imaging industry, a domestic source of high-purity iodine could enhance supply chain security and reduce dependency on foreign sources. Voyageur plans to develop iodine production capacity of up to 1,000 tonnes per year to support its future iodine-based contrast pharmaceutical production. This aligns with the company's broader strategy to vertically integrate across the contrast media value chain, from raw material extraction to final drug manufacturing, a model it is also applying to its Frances Creek barium project.
As Voyageur advances through engineering phases, including concept and basic design, the company expects to refine cost estimates and support future commercial deployment. The successful field pilot will be a critical step in validating the technology's viability at scale, paving the way for broader adoption in the energy and healthcare sectors. The company plans to provide updates as field testing begins and more data is collected.
